索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]孙玉芹,王华亭,李震花.SGLT2抑制剂减少2型糖尿病患者并发心律失常的研究进展[J].国际心血管病杂志,2022,05:257-260.
点击复制

SGLT2抑制剂减少2型糖尿病患者并发心律失常的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年05期
页码:
257-260
栏目:
综述
出版日期:
2022-10-01

文章信息/Info

Title:
-
作者:
孙玉芹; 王华亭; 李震花
261000 潍坊医学院（孙玉芹）；250000 济南市中心医院（王华亭，李震花）
Author(s):
-
关键词:
钠- 葡萄糖协同转运蛋白2 抑制剂; 2 型糖尿病; 心律失常
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.05.001
文献标识码:
-
摘要:
钠- 葡萄糖协同转运蛋白2 抑制剂（SGLT2i）是一种新型降糖药，通过抑制肾 脏近端小管对钠及葡萄糖的重吸收降低血糖。研究证实SGLT2i 能减少心力衰竭的发生率、 住院率及全因死亡率。多项研究提示SGLT2i 可以通过减轻心脏负荷、改善离子稳态、调节 线粒体功能及抑制交感神经活性等机制减少心律失常的发生。该文介绍SGLT2i 通过减少心 律失常发生使心血管系统获益的研究进展。
Abstract:
-

参考文献/References

[1] Gumprecht J, Lip GYH, Sokal A, et al. Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study[J]. Cardiovasc Diabetol, 2021, 20(1):128.
[2] Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2018, 72(15):1845-1855.
[3] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22):2117-2128.
[4] Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial[J]. Am Heart J, 2018, 200:83-89.
[5] Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4):347-357.
[6] Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial[J]. Circulation, 2020, 141(15):1227-1234.
[7] Chen HY, Huang JY, Siao WZ, et al. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study[J]. Cardiovasc Diabetol, 2020, 19(1):73.
[8] Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis[J]. Cardiovasc Diabetol, 2021, 20(1):100.
[9] Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21):1995-2008.
[10] Curtain JP, Docherty KF, Jhund PS, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF[J]. Eur Heart J, 2021, 42(36):3727-3738.
[11] Light PE. Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure[J]. Eur Heart J, 2021, 42(36):3739- 3740.
[12] Lahnwong S, Palee S, Apaijai N, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury[J]. Cardiovasc Diabetol, 2020, 19(1):91.
[13] Azam MA, Chakraborty P, Si D, et al. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia[J]. Life Sci, 2021, 276:119440.
[14] Lahnwong S, Chattipakorn SC, Chattipakorn N. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors[J]. Cardiovasc Diabetol, 2018, 17(1):101.
[15] Li WJ, Chen XQ, Xu LL, et al. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with metaanalysis of 16 randomized controlled trials[J]. Cardiovasc Diabetol, 2020, 19(1):130.
[16] Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal[J]. Physiol Rev, 2011, 91(1):265-325.
[17] Kim YG, Han KD, Choi JI, et al. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study[J]. Cardiovasc Diabetol, 2019, 18(1):128.
[18] Habibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes[J]. Cardiovasc Diabetol, 2017, 16(1):9.
[19] Sato T, Aizawa Y, Yuasa S, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol, 2018, 17(1):6.
[20] Jhuo SJ, Liu IH, Tsai WC, et al. Effects of secretome from fat tissues on ion currents of cardiomyocyte modulated by sodium-glucose transporter 2 inhibitor[J]. Molecules, 2020, 25(16):3606.
[21] Okunrintemi V, Mishriky BM, Powell JR, et al. Sodiumglucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials[J]. Diabetes Obes Metab, 2021, 23(1):276-280.
[22] Gilbert RE, Mende C, Vijapurkar U, et al. Effects of canagliflozin on serum magnesium in patients with type 2 diabetes mellitus: a post hoc analysis of randomized controlled trials[J]. Diabetes Ther, 2017, 8(2):451-458.
[23] Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na＋ through inhibition of the cardiac Na＋/H＋ exchanger in rats and rabbits[J]. Diabetologia, 2017, 60(3):568-573.
[24] Durak A, Olgar Y, Degirmenci S, et al. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulinresistant metabolic syndrome rats[J]. Cardiovasc Diabetol, 2018, 17(1):144.
[25] Shao Q, Meng L, Lee S, et al. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/ streptozotocin-induced diabetic rats[J]. Cardiovasc Diabetol, 2019, 18(1):165.
[26] Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, et al. Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury[J]. J Endocrinol, 2018, 236(2):69-84.
[27] Alabas OA, Hall M, Dondo TB, et al. Long-term excess mortality associated with diabetes following acute myocardial infarction: a population-based cohort study[J]. J Epidemiol Community Health, 2017, 71(1):25-32.
[28] Fukuda K, Kanazawa H, Aizawa Y, et al. Cardiac innervation and sudden cardiac death[J]. Circ Res, 2015,116(12):2005- 2019.
[29] Shimizu W, Kubota Y, Hoshika Y, et al. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial[J]. Cardiovasc Diabetol, 2020, 19(1):148.
[30] Herat LY, Magno AL, Rudnicka C, et al. SGLT2 inhibitorinduced sympathoinhibition: a novel mechanism for cardiorenal protection[J]. JACC Basic Transl Sci, 2020, 5(2):169-179.

备注/Memo

备注/Memo:
通信作者：王华亭， E-mail：15318816020@163.com
更新日期/Last Update: 2022-10-01